


MEDICINAL PRODUCTS 2023

Ingevity Corp Rank 29 of 48







RealRate

MEDICINAL PRODUCTS 2023

Ingevity Corp Rank 29 of 48



The relative strengths and weaknesses of Ingevity Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ingevity Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 49% points. The greatest weakness of Ingevity Corp is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 32%, being 37% points above the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	679,000
Assets, Non-Current	142,100
General and Administrative Expense	1,297,000
Goodwill	923,300
Liabilities, Current	410,000
Liabilities, Non-Current	1,628,200
Other Assets	193,500
Other Compr. Net Income	-59,900
Other Expenses	138,600
Other Liabilities	0
Other Net Income	9,200
Other Revenues	1,668,300
Property, Plant and Equipment, Net	798,600
Research and Development	30,300

Output Variable	Value in 1000 USD
Liabilities	2,038,200
Assets	2,736,500
Expenses	1,465,900
Revenues	1,668,300
Stockholders Equity	698,300
Net Income	211,600
Comprehensive Net Income	181,650
Economic Capital Ratio	32%

